Kudrna's Stock Market Talk

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit (without being able to print money), among other areas.  Hopefully I can resume the normal article schedule this summer.  Remember, I’m a trader first and an author second which keeps this site free. Make sure you spend some time in the live-chat with our other seasoned traders as well as keep up to date with our other authors on the site.  (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit (without being able to print money), among other areas.  Hopefully I can resume the normal article schedule soon.  Remember, I’m a trader first and an author second which keeps this site free. Make sure you spend some time in the live-chat with our other seasoned traders as well as keep up to date with our other authors on the site.  (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit (without being able to print money), among other areas.  Hopefully I can resume the normal article schedule soon.  Remember, I’m a trader first and an author second which keeps this site free. Make sure you spend some time in the live-chat with our other seasoned traders as well as keep up to date with our other authors on the site.  (more…)

On April 17, 2012, Depomed (DEPO) announced it had completed a Type B “pre-NDA” meeting with the U.S. FDA regarding the results of the three phase 3 clinical trials for Serada (extended-release gabapentin tablets). Following the meeting, management believes the data from the BREEZE-1, -2, and -3 trials “warrants submission of an NDA for the FDA’s review and consideration” for the treatment of menopausal hot flashes. (more…)

In the StockTalk posted Monday 4/16 before market opened, I pointed out that AAPL stock price faced the first real serious challenge since the uptrend started on 12/5/2011. (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit, among other areas.  Hopefully I can resume the normal article schedule soon.  Remember, I’m a trader first and an author second which keeps this site free.  (more…)

This morning, InVivo Therapeutics (NVIV) announced significant news relating to the advancement of the company’s biopolymer scaffolding device to treat acute spinal cord injury. Management recently met with the U.S. FDA to discuss the Investigational Device Expemption (IDE) and the planned human clinical study. Talks centered around the inclusion / exclusion criteria, along with defining the starting and stopping points for the trial. This is a first of its kind program, and one that we’ve written about previously as being potentially revolutionary for the treatment of acute spinal cord injury. (more…)

We recommend investors keep an eye on Spherix, Inc. (SPEX). The stock has a history of quick rallies on news, followed by quick sell-offs on subsequent dilutive financings. The company has several catalysts coming up over the next few quarters that could provide meaningful opportunities for investors. (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix it to break-even. Hopefully I can resume the normal article schedule soon.  Remember, I’m a trader first and an author second which keeps this site free.  (more…)

On May 4, 2012, the U.S. FDA is expected to rule on the approval of Alexza Pharmaceuticals’ (ALXA) Adasuve (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia and bipolar disorder. The decision has already been delayed by three months from the original (“PDUFA”) action date set by the FDA of February 4, 2012. I view the decision as make-or-break for Alexza, a company that has already significantly reduced its staff in an effort to limit operating burn ahead of the decision. (more…)